GlobeNewsWire
21 Nov 2026, 00:55 UTC · 2h ago
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Impact · against what's priced in
Capricor Therapeutics faces a severe setback following an FDA Complete Response Letter for Deramiocel, citing insufficient evidence of effectiveness. This failure on a resubmitted BLA significantly impairs the company's primary growth catalyst for Duchenne muscular dystrophy.
- CAPR−1.00
No priced-in read yet





